이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

정신분열증 환자에서 CPL500036(PDE10A 억제제)의 효능, 안전성 및 약동학 연구

2026년 11월 10일 업데이트: Celon Pharma SA

II상, 이중 맹검, 무작위배정, 위약 대조, 병렬 그룹, 정신분열증의 급성 악화 환자에서 CPL500036(PDE10A 억제제)의 효능, 안전성 및 약동학을 탐색하기 위한 시험

The purpose of this study is to determine the efficacy, safety, tolerability and pharmacokinetics (PK) properties of CPL500036 compound (PDE10a inhibitor) in patients with an acute exacerbation of schizophrenia after 28 days of administration..

연구 개요

상세 설명

This is a double-blind, randomized, placebo controlled, parallel group, dose ranging study to explore the efficacy, safety, tolerability and PK of 2 different doses of CPL500036 (phosphodiesterase 10A [PDE10A] inhibitor) in patients with an acute exacerbation of schizophrenia. Approximately 165 patients will be randomized at a 1:1:1 ratio and will be dosed with 20 mg CPL500036, 40 mg CPL500036 or placebo once daily for 28 consecutive days (Day 1 to Day 28). Patients will remain in house for the duration of the Treatment Period. The study will comprise of a Screening Period (that will include a prior Medication Washout Period), a Treatment Period and a Follow-up Period. After discharge from the Clinical Unit, patients will return to the Clinical Unit for 2 once weekly Follow-up Visits. Approximately 30% of the patients (17 patients in each of the 3 treatment groups) will undergo extensive PK sampling during the Treatment Period, and the remaining 70% of the patients will only undergo sparse PK sampling.

연구 유형

중재적

등록 (실제)

189

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Ivano-Frankivsk, 우크라이나, 76014
        • Ivano-Frankivsk National Medical University, Department of Psychiatry, Narcology and Medical Psychology
      • Kyiv, 우크라이나, 04080
        • Communal non-profit enterprise "Clinical Hospital "PSYCHIATRY"" of the executive body of the Kyiv City Council (Kyiv City State Administration), Center for Primary Psychotic Episode and Modern Treatment Methods.
      • Kyiv, 우크라이나, 08631
        • Communal non-commercial enterprise of the Kyiv Regional Council "Regional Psychiatric-Narcological Medical Association", women's department No. 2, men's department No. 10.
      • Lviv, 우크라이나, 79017
        • Communal non-commercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Psychoneurological Dispensary",
      • Lviv, 우크라이나, 79021
        • Communal non- commercial enterprise of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital",
      • Ternopil, 우크라이나, 46001
        • Ternopil National Medical University named after I.Y. Gorbachevskiy of the Ministry of Health of Ukraine, Department of Psychiatry, Narcology and Medical Psychology
      • Vinnytsia, 우크라이나, 21018
        • Vinnytsia National Medical University named after M.I. Pirogov, Department of Psychiatry, Narcology and Psychotherapy with a course of postgraduate education
      • Bialystok, 폴란드, 15-272
        • Uniwersytecki Szpital Kliniczny
      • Bolesławiec, 폴란드, 59-700
        • Wojewódzki Szpital dla Nerwowo i Psychicznie Chorych
      • Choroszcz, 폴란드, 16-070
        • Samodzielny Publiczny Psychiatryczny Zakład Opieki Zdrowotnej
      • Gmina Świecie, 폴란드, 86-100
        • Wojewódzki Szpital dla Psychicznie i Nerwowo Chorych
      • Budapest, 헝가리, H-1083
        • Department of Psychiatry and Psychotheraapy of Semmelweis University
      • Budapest, 헝가리, H-1085
        • Semmelweis University, Faculty of Medicine, Department of Psychiatry and Psychotherapy
      • Győr, 헝가리, H-9024
        • Department of Psychiatry, Mental hygiene and Addictology of Petz Aladár County Teaching Hospital
      • Kalocsa, 헝가리, H-6300
        • Bács-Kiskun County Teaching Hospital Kalocsa Holy Cross Hospital
      • Szekszárd, 헝가리, H-7100
        • Psychiatry Department of Tolna County Balassa Janos Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. The patient has a primary diagnosis of schizophrenia confirmed by clinical interview [SCID-5-CT].
  2. Male or female patient aged 18 to 65, inclusive, at Screening.
  3. The patient's with exacerbation of psychotic symptoms
  4. The patient has a score of 5 or higher in 3 or more items of the following PANSS items at Screening and Baseline
  5. The patient has a PANSS Total Score of 80 or higher during Screening and on Baseline
  6. The patient of childbearing potential willing to use acceptable forms of contraception.
  7. The patient has a score in CGI-S scale of 4 or greater at Screening and on Baseline
  8. The patient is able to and agrees to remain off prior antipsychotic medication and all excluded medications as outlined in the protocol for the duration of the Treatment Period.
  9. The patient is able to sign informed consent after receiving information about the trial and has the ability and willingness to comply with the requirements and restrictions of the study protocol.

Exclusion Criteria:

  1. The patient has a decrease in the PANSS Total Score at Baseline compared with the Total Score at Screening.
  2. Patient who recently participated in another interventional clinical study with an Investigational Medicinal Product.
  3. The patient has uncontrolled abnormality which may impact the ability of the patient to participate or potentially confound the study results.
  4. The patient has a history of severe head injury, traumatic brain injury, myocardial infarction or stroke.
  5. The patient has a moderate or severe substance use disorder for alcohol or other substances of abuse except nicotine or caffeine.
  6. The patient is pregnant or lactating or intending to become pregnant or intending to donate ova.
  7. The patient has a history of or known personality disorder or other psychiatric disorder that, in the opinion of the Investigator, would interfere with participation in the study.
  8. The patient is considered by the Investigator to be at imminent risk of suicide or injury to self or others.
  9. The patient has chronic movement disorder that may interfere with the interpretation of study results.
  10. The patient has any existing or previous history of cancer or has newly diagnosed diabetes.
  11. The patient has long QT syndrome or is under treatment with antiarrhythmic drugs.
  12. The patient is considered to be treatment resistant. .
  13. The patient has received electroconvulsive therapy.
  14. The patient has any laboratory values outside the normal range that are considered by the Investigator to be clinically significant at Screening.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: CPL500036 low dose

Patients are to receive 20 mg of CPL500036 administered once dail for 28-days treatment period.

CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.

실험적: CPL500036 high dose

Patients are to receive 40 mg of CPL500036 administered once dail for 28-days treatment period.

CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.

위약 비교기: Placebo

Patients are to receive placebo administered once dail for 28-days treatment period.

Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline in PANSS Positive Subscale at Week 4.
기간: Day -1, Week 4

The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression).

The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112).

Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia.

Day -1, Week 4

2차 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline in PANSS Positive Subscale at Week 1, 2 and 3
기간: Day -1, Week 1, 2 and 3

The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression).

The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112).

Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia.

Day -1, Week 1, 2 and 3
Change From Baseline in PANSS Total Score at Weeks 1, 2, 3, 4
기간: Day -1, Week 1, 2, 3 and 4

The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression).

The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112).

Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia.

Day -1, Week 1, 2, 3 and 4
Change From Baseline in PANSS Subscales Using the Marder 5 Factor Model at Weeks 1, 2, 3, and 4
기간: Day -1, Week 1, 2, 3 and 4

The Positive and Negative Syndrom Scale (PANSS) Marder 5-Factor Model is a structure used for the Positive and Negative Syndrome Scale (as original PANSS scale), but breaking its 30 items (from positive, negative and general psychopathology groups) into five key symptom domains: Positive (8 items: Range 8-56), Negative (7 items: Range 7-49), Disorganized thoughts (7 items: Range 7-49), Uncontrolled hostility/excitement (4 items: Range 4-28), and Anxiety/depression (4 items: Range 4-28). The higher score in subscale, the more severe schizophrenia.

Day -1, Week 1, 2, 3 and 4
Change From Baseline in PANSS Negative Subscales at Weeks 1, 2, 3 and 4
기간: Day -1, Week 1, 2, 3 and 4

The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression).

The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112).

Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia.

Day -1, Week 1, 2, 3 and 4
Change From Baseline in PANSS General Psychopathology Subscale at Weeks 1, 2, 3 and 4
기간: Day -1, Week 1, 2, 3 and 4

The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression).

The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112).

Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia.

Day -1, Week 1, 2, 3 and 4
Percentage of Clinical Responders Based on the PANSS Total Score.
기간: Day -1, Week 1, 2, 3 and 4

The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression).

The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112).

Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia.

Clinical responder is defined as a ≥ 30% decrease from baseline.

Day -1, Week 1, 2, 3 and 4
Change From Baseline in Clinical Global Impression Severity (CGI-S) Score at Weeks 1, 2, 3, and 4
기간: Day -1, Week 1, 2, 3 and 4

CGI-S scale is a physician-rated scale that is designed to rate the severity of the patient's illness at the time of assessment. It is a 7-point assessment where 1= normal (not at all ill) and 7 = among the most extremely ill patients.

Day -1, Week 1, 2, 3 and 4
Clinical Global Impression Scale Improvement (CGI-I) Score at Weeks 1, 2, 3, 4.
기간: Day -1, Week 1, 2, 3 and 4

CGI-I is a 7 points scale that requires the clinician to assess how much the patient's illness has improved or worsened during treatment. It is a 7-point assessment where 1= Very much improved and 7 = Very much worse

Day -1, Week 1, 2, 3 and 4
Percentage of Clinical Responders Based on the CGI-I Score.
기간: Day -1, Week 1, 2, 3 and 4
Day -1, Week 1, 2, 3 and 4
Change From Baseline in Brief Assessment of Cognition in Schizophrenia (BACS) T-Score at Weeks 2 and 4.
기간: Day -1, Week 2 and 4

Brief Assessment Cognition in Schizophrenia (BACS) is specifically designed to measure treatment-related improvements in cognition. A BACS T-score indicating cognitive performance of patients with schizophrenia with a mean of 50 and SD of 10, used for evaluating brain function. Scores are standardized, compared a person's with cognition impairment to a normative group, with scores below 50 indicating poorer performance (lower scores suggest greater difficulty) and above 50 better.

Day -1, Week 2 and 4
Number of Abnormal Physical, Neurological, Ophthalmological and Dermatological Examination Findings.
기간: up to 6 weeks
up to 6 weeks
Number of Adverse Events.
기간: up to 6 weeks

All adverse events that occurence during study were assessed.

up to 6 weeks
Number of Abnormal Clinically Significant Values in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate) Results.
기간: up to 6 weeks
up to 6 weeks
Number of Abnormal Clinically Significant Values in Laboratory Tests (Hematologic, Clinical Chemistry, Coagulation and Urinalysis) Results.
기간: up to 6 weeks
up to 6 weeks
Number of Abnormal Clinically Significant Findings in Electrocardiogram Results.
기간: up to 6 weeks

The following electrocardiogram parameters were assessed: PR interval, QRS interval, RR interval, QT interval and QTc interval.

up to 6 weeks
Number and Intensity of Extrapyramidal Side Effects.
기간: up to 6 weeks

It was assessed by Extrapyramidal Symptom Rating Scale (ESRS). This scale is using to assess four types of drug-induced movement disorders (DIMD): Parkinsonism, akathisia, dystonia, and tardive dyskinesia.

up to 6 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 5월 19일

기본 완료 (실제)

2024년 6월 5일

연구 완료 (실제)

2024년 6월 19일

연구 등록 날짜

최초 제출

2022년 2월 9일

QC 기준을 충족하는 최초 제출

2022년 3월 3일

처음 게시됨 (실제)

2022년 3월 14일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2025년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 02PDE2019

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다